Genfit shares reiterate buy rating on royalty news

EditorNatashya Angelica
Published 09/23/2024, 09:40 AM
GNFT
-


On Monday, H.C. Wainwright maintained a Buy rating and a $13.00 price target for Genfit (NASDAQ:GNFT) shares, a biopharmaceutical company. The firm's analyst highlighted the commencement of royalty payments by Genfit to its partner Ipsen for the drug Iqirvo, which is used to treat Primary Biliary Cholangitis (PBC).

Genfit has started the invoicing process for the first U.S. royalty payments to Ipsen. This follows Ipsen's acquisition of the global rights to develop and market Iqirvo, with the exception of certain Asian regions. Since June 2024, Ipsen has been marketing Iqirvo in the U.S. Genfit received a milestone payment of €48.7 million from Ipsen after the first U.S. commercial sale of Iqirvo, which was invoiced in June and received by August. The company is also entitled to tiered double-digit net sales royalties of up to 20%.

The company is anticipating a decision from the European Commission (EC) on market authorization for Iqirvo in Europe in the second half of 2024. A positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in July supports the likelihood of approval. Additionally, a pricing and reimbursement approval in three European countries would lead to a milestone payment of €26.5 million.

Beyond Iqirvo, Genfit is looking forward to potential milestones from its programs targeting acute on chronic liver failure (ACLF) and its cholangiocarcinoma (CCA) candidate, GNS561. The company's focus has largely shifted to these areas since the partnership with Ipsen for Iqirvo.

With the U.S. commercialization underway and the European decision pending, Genfit's partnership with Ipsen is poised to provide ongoing revenue through royalties and potential milestone payments. The firm expressed a positive outlook for Iqirvo's market authorization in Europe and the U.K., which would further contribute to Genfit's financial growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.